SIMILAR PATTERNS OF AMINO ACIDS FOR 5T2Z_B_017B201_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1fob	BETA-1,4-GALACTANASE (Aspergillus aculeatus)	PF07745 (Glyco_hydro_53)	5	GLY A 40 ALA A 39 ASP A 38 ILE A 44 ILE A 328	None	0.98A	5t2zA-1fobA: undetectable	5t2zA-1fobA: 15.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 VAL A 32 GLY A 48 ILE A 84	A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.4A) A79 A 800 (-3.6A) A79 A 800 (-3.6A)	0.75A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.9A) A79 A 800 (-3.6A)	0.62A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A)	1.21A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-2.8A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A)	1.01A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A) A79 A 800 (-3.6A)	0.46A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 ILE A 84	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A) A79 A 800 (-3.8A)	0.47A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 PRO A 81 ILE A 84	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 (-3.4A) A79 A 800 ( 3.4A) A79 A 800 (-3.8A)	0.44A	5t2zA-1hvcA: 13.0	5t2zA-1hvcA: 39.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1i7p	NADH-CYTOCHROME B5 REDUCTASE (Rattus norvegicus)	PF00175 (NAD_binding_1) PF00970 (FAD_binding_6)	5	ASP A 100 ASP A 101 GLY A 71 PRO A 64 SER A 65	None	1.01A	5t2zA-1i7pA: undetectable	5t2zA-1i7pA: 15.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1kq0	METHIONINE AMINOPEPTIDASE 2 (Homo sapiens)	PF00557 (Peptidase_M24)	5	ASP A 299 VAL A 344 GLY A 292 ILE A 293 SER A 332	None	1.07A	5t2zA-1kq0A: undetectable	5t2zA-1kq0A: 14.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1naa	CELLOBIOSE DEHYDROGENASE (Phanerochaete chrysosporium)	PF00732 (GMC_oxred_N) PF05199 (GMC_oxred_C)	5	GLY A 223 ALA A 224 VAL A 407 GLY A 305 ILE A 229	6FA A 801 (-3.0A) 6FA A 801 ( 4.9A) None 6FA A 801 (-3.5A) None	1.04A	5t2zA-1naaA: undetectable	5t2zA-1naaA: 11.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1o9b	HYPOTHETICAL SHIKIMATE 5-DEHYDROGENASE-LIKE PROTEIN YDIB (Escherichia coli)	PF08501 (Shikimate_dh_N)	5	LEU A 129 GLY A 143 ALA A 144 GLY A 124 ILE A 151	None	1.00A	5t2zA-1o9bA: undetectable	5t2zA-1o9bA: 17.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	5	ALA A 28 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.89A	5t2zA-1q9pA: 9.8	5t2zA-1q9pA: 80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	7	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.55A	5t2zA-1q9pA: 9.8	5t2zA-1q9pA: 80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.23A	5t2zA-1sivA: 18.9	5t2zA-1sivA: 50.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 ILE A 84	None	0.49A	5t2zA-1sivA: 18.9	5t2zA-1sivA: 50.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 ILE A 84	None	0.53A	5t2zA-1sivA: 18.9	5t2zA-1sivA: 50.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1svv	THREONINE ALDOLASE (Leishmania major)	PF01212 (Beta_elim_lyase)	5	ASP A 183 GLY A 184 ALA A 185 GLY A 74 ILE A 72	None	1.08A	5t2zA-1svvA: undetectable	5t2zA-1svvA: 15.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v5f	PYRUVATE OXIDASE (Aerococcus viridans)	PF00205 (TPP_enzyme_M) PF02775 (TPP_enzyme_C) PF02776 (TPP_enzyme_N)	5	ASP A 388 ALA A 444 ASP A 442 VAL A 466 ILE A 440	None TPP A1602 (-3.7A) MG A1603 ( 2.8A) None None	1.02A	5t2zA-1v5fA: undetectable	5t2zA-1v5fA: 10.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v5j	KIAA1355 PROTEIN (Homo sapiens)	PF00041 (fn3)	5	GLY A 85 ALA A 84 VAL A 33 GLY A 60 PRO A 11	None	0.89A	5t2zA-1v5jA: undetectable	5t2zA-1v5jA: 22.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1yg0	COP ASSOCIATED PROTEIN (Helicobacter pylori)	PF00403 (HMA)	5	GLY A 62 ALA A 61 ASP A 60 VAL A 23 ILE A 19	None	1.08A	5t2zA-1yg0A: undetectable	5t2zA-1yg0A: 20.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1yr2	PROLYL OLIGOPEPTIDASE (Novosphingobium capsulatum)	PF00326 (Peptidase_S9) PF02897 (Peptidase_S9_N)	5	GLY A 539 ALA A 538 ASP A 537 GLY A 529 PRO A 475	None	1.00A	5t2zA-1yr2A: undetectable	5t2zA-1yr2A: 9.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2bc0	NADH OXIDASE (Streptococcus pyogenes)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	GLY A 453 ALA A 454 ASP A 456 ILE A 387 ILE A 426	None	0.57A	5t2zA-2bc0A: undetectable	5t2zA-2bc0A: 13.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2bkl	PROLYL ENDOPEPTIDASE (Myxococcus xanthus)	PF00326 (Peptidase_S9) PF02897 (Peptidase_S9_N)	5	GLY A 497 ALA A 496 ASP A 495 GLY A 487 PRO A 431	None	1.03A	5t2zA-2bklA: undetectable	5t2zA-2bklA: 9.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2cvj	THIOREDOXIN REDUCTASE RELATED PROTEIN (Thermus thermophilus)	PF00890 (FAD_binding_2) PF07992 (Pyr_redox_2)	5	LEU A 170 GLY A 24 ALA A 23 ASP A 177 VAL A 164	None	0.95A	5t2zA-2cvjA: undetectable	5t2zA-2cvjA: 20.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 55 PRO A 86 ILE A 89	None LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-3.4A) LP1 A 201 (-3.9A) LP1 A 201 (-4.2A)	0.40A	5t2zA-2fmbA: 15.0	5t2zA-2fmbA: 30.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2p2s	PUTATIVE OXIDOREDUCTASE (Pectobacterium atrosepticum)	PF01408 (GFO_IDH_MocA) PF02894 (GFO_IDH_MocA_C)	5	LEU A 250 GLY A 136 ALA A 135 ILE A 127 ILE A 261	None	0.94A	5t2zA-2p2sA: undetectable	5t2zA-2p2sA: 15.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pl1	TRANSCRIPTIONAL REGULATORY PROTEIN PHOP (Escherichia coli)	PF00072 (Response_reg)	5	LEU A 60 GLY A 94 ALA A 95 ASP A 96 VAL A 50	None	1.04A	5t2zA-2pl1A: undetectable	5t2zA-2pl1A: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2rag	DIPEPTIDASE (Caulobacter vibrioides)	PF01244 (Peptidase_M19)	5	LEU A 268 ALA A 248 ASP A 226 GLY A 358 ILE A 278	None	1.00A	5t2zA-2ragA: undetectable	5t2zA-2ragA: 13.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rkf	PROTEASE RETROPEPSIN (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None AB1 A 501 (-2.4A) AB1 A 501 (-3.9A) AB1 A 501 (-3.5A) AB1 A 501 ( 3.3A) AB1 A 501 (-3.8A) AB1 A 501 (-3.5A) AB1 A 501 (-3.8A) AB1 A 501 (-4.2A) AB1 A 501 ( 4.2A)	0.48A	5t2zA-2rkfA: 20.6	5t2zA-2rkfA: 75.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2rsp	RSV PROTEASE (Rous sarcoma virus)	PF00077 (RVP)	6	LEU A 35 ASP A 37 GLY A 39 ALA A 40 ASP A 41 ILE A 108	None	0.22A	5t2zA-2rspA: 12.9	5t2zA-2rspA: 28.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vn8	RETICULON-4-INTERACT ING PROTEIN 1 (Homo sapiens)	PF08240 (ADH_N) PF13602 (ADH_zinc_N_2)	5	GLY A 248 ALA A 249 ASP A 250 ASP A 251 SER A 214	None None None None NDP A 600 (-2.7A)	1.05A	5t2zA-2vn8A: undetectable	5t2zA-2vn8A: 13.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wd9	ACYL-COENZYME A SYNTHETASE ACSM2A, MITOCHONDRIAL (Homo sapiens)	PF00501 (AMP-binding) PF13193 (AMP-binding_C)	5	GLY A 280 ALA A 281 ASP A 255 GLY A 247 SER A 272	None	0.83A	5t2zA-2wd9A: undetectable	5t2zA-2wd9A: 11.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yhe	SEC-ALKYL SULFATASE (Pseudomonas sp. DSM 6611)	PF00753 (Lactamase_B) PF14863 (Alkyl_sulf_dimr) PF14864 (Alkyl_sulf_C)	5	LEU A 124 ASP A 141 ASP A 278 VAL A 145 ILE A 138	None	1.08A	5t2zA-2yheA: undetectable	5t2zA-2yheA: 10.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yjv	REGULATOR OF RIBONUCLEASE ACTIVITY A (Escherichia coli)	PF03737 (RraA-like)	5	GLY A 67 ASP A 64 VAL A 91 GLY A 134 SER A 24	None	0.77A	5t2zA-2yjvA: undetectable	5t2zA-2yjvA: 21.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yvq	CARBAMOYL-PHOSPHATE SYNTHASE (Homo sapiens)	PF02142 (MGS)	5	ASP A1429 GLY A1361 ILE A1362 PRO A1462 ILE A1427	None	1.06A	5t2zA-2yvqA: undetectable	5t2zA-2yvqA: 18.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3b46	AMINOTRANSFERASE BNA3 (Saccharomyces cerevisiae)	PF00155 (Aminotran_1_2)	5	LEU A 290 GLY A 134 GLY A 127 ILE A 128 SER A 285	None	0.67A	5t2zA-3b46A: undetectable	5t2zA-3b46A: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d43	SPHERICASE (Lysinibacillus sphaericus)	PF00082 (Peptidase_S8)	5	ALA A 97 ASP A 96 GLY A 92 PRO A 254 ILE A 30	None	1.03A	5t2zA-3d43A: undetectable	5t2zA-3d43A: 17.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dbg	PUTATIVE CYTOCHROME P450 (Streptomyces coelicolor)	PF00067 (p450)	5	GLY A 359 ALA A 360 ASP A 361 PRO A 24 ILE A 356	None	0.84A	5t2zA-3dbgA: undetectable	5t2zA-3dbgA: 11.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gve	YFKN PROTEIN (Bacillus subtilis)	PF00149 (Metallophos)	5	GLY A 121 ALA A 122 ASP A 123 ILE A 89 ILE A 126	None	0.74A	5t2zA-3gveA: undetectable	5t2zA-3gveA: 16.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3huu	TRANSCRIPTION REGULATOR LIKE PROTEIN (Staphylococcus haemolyticus)	PF13377 (Peripla_BP_3)	5	LEU A 25 GLY A 259 ALA A 262 GLY A 111 ILE A 86	None	1.06A	5t2zA-3huuA: undetectable	5t2zA-3huuA: 18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i4o	TRANSLATION INITIATION FACTOR IF-1 (Mycobacterium tuberculosis)	PF01176 (eIF-1a)	5	LEU A 27 GLY A 66 ALA A 35 VAL A 14 ILE A 25	None	1.00A	5t2zA-3i4oA: undetectable	5t2zA-3i4oA: 22.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3id3	REGULATOR OF SIGMA E PROTEASE (Escherichia coli)	PF00595 (PDZ)	5	ASP A 244 GLY A 243 VAL A 247 GLY A 280 ILE A 276	None	1.04A	5t2zA-3id3A: undetectable	5t2zA-3id3A: 22.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ifr	CARBOHYDRATE KINASE, FGGY (Rhodospirillum rubrum)	PF00370 (FGGY_N) PF02782 (FGGY_C)	5	ASP A 107 GLY A 108 PRO A 101 SER A 102 ILE A 103	None	1.06A	5t2zA-3ifrA: undetectable	5t2zA-3ifrA: 11.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3k4h	PUTATIVE TRANSCRIPTIONAL REGULATOR (Bacillus cytotoxicus)	PF13377 (Peripla_BP_3)	5	LEU A 13 GLY A 251 ALA A 254 GLY A 99 ILE A 74	None None None MAL A 501 (-3.3A) None	1.06A	5t2zA-3k4hA: undetectable	5t2zA-3k4hA: 15.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kyh	MRNA-CAPPING ENZYME SUBUNIT BETA (Saccharomyces cerevisiae)	PF02940 (mRNA_triPase)	5	ALA A 337 ASP A 336 ASP A 315 VAL A 322 ILE A 313	None	0.96A	5t2zA-3kyhA: undetectable	5t2zA-3kyhA: 15.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lun	ULILYSIN (Methanosarcina acetivorans)	PF05572 (Peptidase_M43)	5	ALA A 209 ASP A 207 VAL A 175 ILE A 93 ILE A 205	None	0.95A	5t2zA-3lunA: undetectable	5t2zA-3lunA: 16.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mq0	TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON (Agrobacterium tumefaciens)	PF01614 (IclR) PF09339 (HTH_IclR)	5	LEU A 240 GLY A 254 VAL A 121 PRO A 118 ILE A 238	None	0.93A	5t2zA-3mq0A: undetectable	5t2zA-3mq0A: 15.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	LEU A 23 ASP A 25 ASP A 29 GLY A 49 PRO A 81	None	1.08A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.52A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nek	NITROGEN REPRESSOR-LIKE PROTEIN MJ0159 (Methanocaldococcus jannaschii)	PF01995 (DUF128)	5	GLY A 457 ALA A 456 GLY A 480 ILE A 376 PRO A 511	GOL A 1 ( 4.7A) None None None None	1.02A	5t2zA-3nekA: undetectable	5t2zA-3nekA: 19.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3owq	LIN1025 PROTEIN (Listeria innocua)	PF03816 (LytR_cpsA_psr)	5	ALA A 169 ASP A 168 GLY A 162 ILE A 158 ILE A 244	None	1.08A	5t2zA-3owqA: undetectable	5t2zA-3owqA: 15.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3p4g	ANTIFREEZE PROTEIN (Marinomonas primoryensis)	no annotation	5	ASP A 103 GLY A 99 ALA A 98 VAL A 124 GLY A 137	CA A 403 ( 2.4A) CA A 403 (-4.1A) CA A 404 (-4.5A) None CA A 405 (-4.1A)	0.98A	5t2zA-3p4gA: undetectable	5t2zA-3p4gA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qc0	SUGAR ISOMERASE (Sinorhizobium meliloti)	PF01261 (AP_endonuc_2)	5	GLY A 66 VAL A 171 GLY A 123 ILE A 81 PRO A 129	None	0.92A	5t2zA-3qc0A: undetectable	5t2zA-3qc0A: 16.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	5	ASP A 32 GLY A 34 ALA A 35 VAL A 39 PRO A 89	3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-4.0A)	0.56A	5t2zA-3slzA: 11.4	5t2zA-3slzA: 29.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	6	LEU A 30 ASP A 32 GLY A 34 ALA A 35 VAL A 39 GLY A 56	None 3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-3.4A)	0.49A	5t2zA-3slzA: 11.4	5t2zA-3slzA: 29.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) 017 A 201 (-4.0A) 017 A 201 (-3.3A)	1.26A	5t2zA-3t3cA: 19.1	5t2zA-3t3cA: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) None 017 A 201 (-4.0A) 017 A 201 (-3.3A)	0.40A	5t2zA-3t3cA: 19.1	5t2zA-3t3cA: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	SO4 A 101 (-4.2A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) None 017 A 201 (-4.0A) 017 A 201 (-3.3A) None	0.54A	5t2zA-3t3cA: 19.1	5t2zA-3t3cA: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-4.6A) 017 A 201 (-3.0A) 017 A 201 (-3.3A) 017 A 201 (-4.1A) 017 A 201 (-4.7A)	0.41A	5t2zA-3ttpA: 20.2	5t2zA-3ttpA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 (-3.4A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	1.29A	5t2zA-3u7sA: 19.8	5t2zA-3u7sA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None 017 A 202 ( 2.5A) 017 A 201 ( 3.5A) 017 A 201 (-3.4A) 017 A 201 (-3.2A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A) 017 A 202 (-4.0A)	0.36A	5t2zA-3u7sA: 19.8	5t2zA-3u7sA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3uhl	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 PRO A 81	None	0.45A	5t2zA-3uhlA: 16.5	5t2zA-3uhlA: 77.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w1j	L-SERYL-TRNA(SEC) SELENIUM TRANSFERASE (Aquifex aeolicus)	PF03841 (SelA)	5	LEU A 211 GLY A 202 ALA A 203 GLY A 190 ILE A 160	None	0.88A	5t2zA-3w1jA: undetectable	5t2zA-3w1jA: 13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wn6	ALPHA-AMYLASE (Oryza sativa)	PF00128 (Alpha-amylase) PF07821 (Alpha-amyl_C2)	5	GLY A 58 ASP A 52 VAL A 51 GLY A 106 ILE A 54	None	1.02A	5t2zA-3wn6A: undetectable	5t2zA-3wn6A: 11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a3x	EPA1P ([Candida] glabrata)	PF10528 (GLEYA)	5	GLY A 172 ALA A 173 ASP A 178 PRO A 52 SER A 51	None	0.91A	5t2zA-4a3xA: undetectable	5t2zA-4a3xA: 18.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4asl	EPA1P ([Candida] glabrata)	PF10528 (GLEYA)	5	GLY A 172 ALA A 173 ASP A 178 PRO A 52 SER A 51	None	0.89A	5t2zA-4aslA: undetectable	5t2zA-4aslA: 20.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cw5	DFNA (Bacillus velezensis)	PF03060 (NMO)	5	GLY A 559 GLY A 732 ILE A 731 PRO A 542 ILE A 539	FMN A1753 (-3.0A) None None None None	0.99A	5t2zA-4cw5A: undetectable	5t2zA-4cw5A: 13.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f7f	AGAP005208-PA (Anopheles gambiae)	PF01395 (PBP_GOBP)	5	GLY A 80 ALA A 79 ASP A 76 SER A 66 ILE A 70	None None None PG6 A 202 ( 4.4A) PG6 A 202 ( 4.9A)	1.03A	5t2zA-4f7fA: undetectable	5t2zA-4f7fA: 19.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ida	RIPENING-INDUCED PROTEIN (Fragaria vesca)	PF08240 (ADH_N) PF13602 (ADH_zinc_N_2)	5	LEU A 203 GLY A 208 ALA A 209 ASP A 210 ILE A 179	None	0.88A	5t2zA-4idaA: undetectable	5t2zA-4idaA: 17.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4iqy	O-ACETYL-ADP-RIBOSE DEACETYLASE MACROD2 (Homo sapiens)	PF01661 (Macro)	5	GLY A 191 ALA A 149 GLY A 146 ILE A 185 ILE A 153	None	0.90A	5t2zA-4iqyA: undetectable	5t2zA-4iqyA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4kpo	NUCLEOSIDE N-RIBOHYDROLASE 3 (Zea mays)	PF01156 (IU_nuc_hydro)	5	GLY A 10 ASP A 12 GLY A 124 ILE A 34 ILE A 17	None CA A 401 ( 4.8A) CA A 401 ( 4.3A) None None	0.88A	5t2zA-4kpoA: undetectable	5t2zA-4kpoA: 21.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mch	URIDINE PHOSPHORYLASE (Aliivibrio fischeri)	PF01048 (PNP_UDP_1)	5	LEU A 176 GLY A 92 ALA A 91 GLY A 101 ILE A 104	None DMS A 515 ( 4.1A) None None None	1.09A	5t2zA-4mchA: undetectable	5t2zA-4mchA: 19.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 ILE A 84	RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-4.8A) RIT A 500 (-4.3A)	0.73A	5t2zA-4njvA: 19.9	5t2zA-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50	None RIT A 500 (-2.4A) RIT A 500 (-3.2A) RIT A 500 (-3.4A) RIT A 500 (-4.3A)	1.03A	5t2zA-4njvA: 19.9	5t2zA-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-3.9A) RIT A 500 (-4.3A)	0.51A	5t2zA-4njvA: 19.9	5t2zA-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) None RIT A 500 (-3.4A) RIT A 500 (-4.3A) RIT A 500 (-4.3A)	0.44A	5t2zA-4njvA: 19.9	5t2zA-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 PRO A 81 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) None RIT A 500 (-3.4A) RIT A 500 (-3.9A) RIT A 500 (-4.3A)	0.46A	5t2zA-4njvA: 19.9	5t2zA-4njvA: 85.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pmw	DIS3-LIKE EXONUCLEASE 2 (Mus musculus)	PF00773 (RNB) PF17216 (Rrp44_CSD1)	5	LEU A 265 ASP A 282 ILE A 303 PRO A 268 SER A 267	None None None None U C 1 ( 3.7A)	0.84A	5t2zA-4pmwA: undetectable	5t2zA-4pmwA: 7.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pyr	PUTATIVE BRANCHED-CHAIN AMINO ACID ABC TRANSPORTER (Chromobacterium violaceum)	PF04348 (LppC)	5	ALA A 343 VAL A 88 GLY A 336 ILE A 337 ILE A 86	None	1.05A	5t2zA-4pyrA: undetectable	5t2zA-4pyrA: 16.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tl9	CIRCADIAN CLOCK PROTEIN KINASE KAIC (Synechococcus elongatus)	PF06745 (ATPase)	5	ALA A 87 GLY A 243 ILE A 239 SER A 56 ILE A 57	None None AGS A 303 ( 3.9A) None None	0.85A	5t2zA-4tl9A: undetectable	5t2zA-4tl9A: 19.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	7	LEU A 30 ASP A 32 GLY A 34 ALA A 35 ASP A 36 GLY A 58 ILE A 100	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) 4B1 A 201 (-3.4A) 4B1 A 201 (-4.8A)	0.43A	5t2zA-4ydfA: 12.4	5t2zA-4ydfA: 33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	6	LEU A 30 ASP A 32 GLY A 34 ALA A 35 ASP A 36 VAL A 39	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) None	0.43A	5t2zA-4ydfA: 12.4	5t2zA-4ydfA: 33.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z38	MLNA (Bacillus velezensis)	no annotation	5	GLY A 576 GLY A 748 ILE A 747 PRO A 559 ILE A 556	FMN A 900 (-3.5A) None None None None	1.01A	5t2zA-4z38A: undetectable	5t2zA-4z38A: 12.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z38	MLNA (Bacillus velezensis)	no annotation	5	GLY A 576 GLY A 748 ILE A 747 SER A 561 ILE A 556	FMN A 900 (-3.5A) None None None None	1.08A	5t2zA-4z38A: undetectable	5t2zA-4z38A: 12.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None	0.40A	5t2zA-5b18A: 17.9	5t2zA-5b18A: 76.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ctm	BETA-LACTAMASE (Bacillus pumilus)	PF00905 (Transpeptidase)	5	LEU A 262 VAL A 87 GLY A 73 ILE A 266 PRO A 197	None	1.08A	5t2zA-5ctmA: undetectable	5t2zA-5ctmA: 17.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5cwa	ANTHRANILATE SYNTHASE COMPONENT 1 (Mycobacterium tuberculosis)	PF00425 (Chorismate_bind) PF04715 (Anth_synt_I_N)	5	LEU A 125 ASP A 447 GLY A 450 ALA A 449 ASP A 115	None	1.08A	5t2zA-5cwaA: undetectable	5t2zA-5cwaA: 12.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5erb	POLYKETIDE SYNTHASE (Bacillus amyloliquefaciens)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C) PF16197 (KAsynt_C_assoc)	5	LEU A 187 GLY A 208 ALA A 207 ILE A 14 ILE A 190	None	1.07A	5t2zA-5erbA: undetectable	5t2zA-5erbA: 11.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5g5g	PUTATIVE XANTHINE DEHYDROGENASE YAGT IRON-SULFUR-BINDING SUBUNIT (Escherichia coli)	PF00111 (Fer2) PF01799 (Fer2_2)	5	GLY A 211 ALA A 212 ASP A 154 GLY A 159 ILE A 216	None None None FES A 230 (-4.2A) None	0.81A	5t2zA-5g5gA: undetectable	5t2zA-5g5gA: 22.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gw4	T-COMPLEX PROTEIN 1 SUBUNIT GAMMA (Saccharomyces cerevisiae)	PF00118 (Cpn60_TCP1)	5	ALA g 399 ASP g 398 GLY g 160 ILE g 165 ILE g 155	None	1.03A	5t2zA-5gw4g: undetectable	5t2zA-5gw4g: 13.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 825 ALA A 824 ILE A 137 SER A 810 ILE A 814	None	1.00A	5t2zA-5lohA: undetectable	5t2zA-5lohA: 14.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xj1	UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029 (Streptococcus pneumoniae)	no annotation	5	GLY A 399 ALA A 400 ASP A 401 ILE A 373 ILE A 378	None	0.85A	5t2zA-5xj1A: undetectable	5t2zA-5xj1A: 13.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	6	LEU A 28 ASP A 30 GLY A 32 ALA A 33 ASP A 34 GLY A 58	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) 3TL A 201 (-3.4A)	0.19A	5t2zA-6fivA: 15.7	5t2zA-6fivA: 30.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) None None	0.64A	5t2zA-6upjA: 18.4	5t2zA-6upjA: 49.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) None	0.65A	5t2zA-6upjA: 18.4	5t2zA-6upjA: 49.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None None	0.85A	5t2zA-6upjA: 18.4	5t2zA-6upjA: 49.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 GLY A 27 ASP A 29 ASP A 30 GLY A 49 ILE A 50 ILE A 84	None NIU A 100 (-4.5A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.81A	5t2zA-6upjA: 18.4	5t2zA-6upjA: 49.49

[["5T2Z_B_017B201_1","1fob","Aspergillus aculeatus","BETA-1,4-GALACTANASE","PF07745(Glyco_hydro_53)",5,"GLY A  40;ALA A  39;ASP A  38;ILE A  44;ILE A 328","None","0.98A","5t2zA-1fobA:undetectable","5t2zA-1fobA:15.62"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;ILE A  84","A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.4A);A79 A 800 (-3.6A);A79 A 800 (-3.6A)","0.75A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.9A);A79 A 800 (-3.6A)","0.62A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A)","1.21A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",5,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-2.8A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A)","1.01A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A);A79 A 800 (-3.6A)","0.46A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;ILE A  84","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A);A79 A 800 (-3.8A)","0.47A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;PRO A  81;ILE A  84","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 (-3.4A);A79 A 800 ( 3.4A);A79 A 800 (-3.8A)","0.44A","5t2zA-1hvcA:13.0","5t2zA-1hvcA:39.90"],["5T2Z_B_017B201_1","1i7p","Rattus norvegicus","NADH-CYTOCHROME B5 REDUCTASE","PF00175(NAD_binding_1);PF00970(FAD_binding_6)",5,"ASP A 100;ASP A 101;GLY A  71;PRO A  64;SER A  65","None","1.01A","5t2zA-1i7pA:undetectable","5t2zA-1i7pA:15.88"],["5T2Z_B_017B201_1","1kq0","Homo sapiens","METHIONINE AMINOPEPTIDASE 2","PF00557(Peptidase_M24)",5,"ASP A 299;VAL A 344;GLY A 292;ILE A 293;SER A 332","None","1.07A","5t2zA-1kq0A:undetectable","5t2zA-1kq0A:14.25"],["5T2Z_B_017B201_1","1naa","Phanerochaete chrysosporium","CELLOBIOSE DEHYDROGENASE","PF00732(GMC_oxred_N);PF05199(GMC_oxred_C)",5,"GLY A 223;ALA A 224;VAL A 407;GLY A 305;ILE A 229","6FA A 801 (-3.0A);6FA A 801 ( 4.9A);None;6FA A 801 (-3.5A);None","1.04A","5t2zA-1naaA:undetectable","5t2zA-1naaA:11.04"],["5T2Z_B_017B201_1","1o9b","Escherichia coli","HYPOTHETICAL SHIKIMATE 5-DEHYDROGENASE-LIKE PROTEIN YDIB","PF08501(Shikimate_dh_N)",5,"LEU A 129;GLY A 143;ALA A 144;GLY A 124;ILE A 151","None","1.00A","5t2zA-1o9bA:undetectable","5t2zA-1o9bA:17.82"],["5T2Z_B_017B201_1","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.89A","5t2zA-1q9pA:9.8","5t2zA-1q9pA:80.00"],["5T2Z_B_017B201_1","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.55A","5t2zA-1q9pA:9.8","5t2zA-1q9pA:80.00"],["5T2Z_B_017B201_1","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.23A","5t2zA-1sivA:18.9","5t2zA-1sivA:50.51"],["5T2Z_B_017B201_1","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;ILE A  84","None","0.49A","5t2zA-1sivA:18.9","5t2zA-1sivA:50.51"],["5T2Z_B_017B201_1","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;ILE A  84","None","0.53A","5t2zA-1sivA:18.9","5t2zA-1sivA:50.51"],["5T2Z_B_017B201_1","1svv","Leishmania major","THREONINE ALDOLASE","PF01212(Beta_elim_lyase)",5,"ASP A 183;GLY A 184;ALA A 185;GLY A  74;ILE A  72","None","1.08A","5t2zA-1svvA:undetectable","5t2zA-1svvA:15.57"],["5T2Z_B_017B201_1","1v5f","Aerococcus viridans","PYRUVATE OXIDASE","PF00205(TPP_enzyme_M);PF02775(TPP_enzyme_C);PF02776(TPP_enzyme_N)",5,"ASP A 388;ALA A 444;ASP A 442;VAL A 466;ILE A 440","None;TPP A1602 (-3.7A); MG A1603 ( 2.8A);None;None","1.02A","5t2zA-1v5fA:undetectable","5t2zA-1v5fA:10.80"],["5T2Z_B_017B201_1","1v5j","Homo sapiens","KIAA1355 PROTEIN","PF00041(fn3)",5,"GLY A  85;ALA A  84;VAL A  33;GLY A  60;PRO A  11","None","0.89A","5t2zA-1v5jA:undetectable","5t2zA-1v5jA:22.52"],["5T2Z_B_017B201_1","1yg0","Helicobacter pylori","COP ASSOCIATED PROTEIN","PF00403(HMA)",5,"GLY A  62;ALA A  61;ASP A  60;VAL A  23;ILE A  19","None","1.08A","5t2zA-1yg0A:undetectable","5t2zA-1yg0A:20.20"],["5T2Z_B_017B201_1","1yr2","Novosphingobium capsulatum","PROLYL OLIGOPEPTIDASE","PF00326(Peptidase_S9);PF02897(Peptidase_S9_N)",5,"GLY A 539;ALA A 538;ASP A 537;GLY A 529;PRO A 475","None","1.00A","5t2zA-1yr2A:undetectable","5t2zA-1yr2A:9.24"],["5T2Z_B_017B201_1","2bc0","Streptococcus pyogenes","NADH OXIDASE","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"GLY A 453;ALA A 454;ASP A 456;ILE A 387;ILE A 426","None","0.57A","5t2zA-2bc0A:undetectable","5t2zA-2bc0A:13.22"],["5T2Z_B_017B201_1","2bkl","Myxococcus xanthus","PROLYL ENDOPEPTIDASE","PF00326(Peptidase_S9);PF02897(Peptidase_S9_N)",5,"GLY A 497;ALA A 496;ASP A 495;GLY A 487;PRO A 431","None","1.03A","5t2zA-2bklA:undetectable","5t2zA-2bklA:9.90"],["5T2Z_B_017B201_1","2cvj","Thermus thermophilus","THIOREDOXIN REDUCTASE RELATED PROTEIN","PF00890(FAD_binding_2);PF07992(Pyr_redox_2)",5,"LEU A 170;GLY A  24;ALA A  23;ASP A 177;VAL A 164","None","0.95A","5t2zA-2cvjA:undetectable","5t2zA-2cvjA:20.11"],["5T2Z_B_017B201_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  55;PRO A  86;ILE A  89","None;LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-3.4A);LP1 A 201 (-3.9A);LP1 A 201 (-4.2A)","0.40A","5t2zA-2fmbA:15.0","5t2zA-2fmbA:30.77"],["5T2Z_B_017B201_1","2p2s","Pectobacterium atrosepticum","PUTATIVE OXIDOREDUCTASE","PF01408(GFO_IDH_MocA);PF02894(GFO_IDH_MocA_C)",5,"LEU A 250;GLY A 136;ALA A 135;ILE A 127;ILE A 261","None","0.94A","5t2zA-2p2sA:undetectable","5t2zA-2p2sA:15.87"],["5T2Z_B_017B201_1","2pl1","Escherichia coli","TRANSCRIPTIONAL REGULATORY PROTEIN PHOP","PF00072(Response_reg)",5,"LEU A  60;GLY A  94;ALA A  95;ASP A  96;VAL A  50","None","1.04A","5t2zA-2pl1A:undetectable","5t2zA-2pl1A:22.22"],["5T2Z_B_017B201_1","2rag","Caulobacter vibrioides","DIPEPTIDASE","PF01244(Peptidase_M19)",5,"LEU A 268;ALA A 248;ASP A 226;GLY A 358;ILE A 278","None","1.00A","5t2zA-2ragA:undetectable","5t2zA-2ragA:13.60"],["5T2Z_B_017B201_1","2rkf","Human immunodeficiency virus 1","PROTEASE RETROPEPSIN","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;AB1 A 501 (-2.4A);AB1 A 501 (-3.9A);AB1 A 501 (-3.5A);AB1 A 501 ( 3.3A);AB1 A 501 (-3.8A);AB1 A 501 (-3.5A);AB1 A 501 (-3.8A);AB1 A 501 (-4.2A);AB1 A 501 ( 4.2A)","0.48A","5t2zA-2rkfA:20.6","5t2zA-2rkfA:75.76"],["5T2Z_B_017B201_1","2rsp","Rous sarcoma virus","RSV PROTEASE","PF00077(RVP)",6,"LEU A  35;ASP A  37;GLY A  39;ALA A  40;ASP A  41;ILE A 108","None","0.22A","5t2zA-2rspA:12.9","5t2zA-2rspA:28.23"],["5T2Z_B_017B201_1","2vn8","Homo sapiens","RETICULON-4-INTERACTING PROTEIN 1","PF08240(ADH_N);PF13602(ADH_zinc_N_2)",5,"GLY A 248;ALA A 249;ASP A 250;ASP A 251;SER A 214","None;None;None;None;NDP A 600 (-2.7A)","1.05A","5t2zA-2vn8A:undetectable","5t2zA-2vn8A:13.83"],["5T2Z_B_017B201_1","2wd9","Homo sapiens","ACYL-COENZYME A SYNTHETASE ACSM2A, MITOCHONDRIAL","PF00501(AMP-binding);PF13193(AMP-binding_C)",5,"GLY A 280;ALA A 281;ASP A 255;GLY A 247;SER A 272","None","0.83A","5t2zA-2wd9A:undetectable","5t2zA-2wd9A:11.58"],["5T2Z_B_017B201_1","2yhe","Pseudomonas sp. DSM 6611","SEC-ALKYL SULFATASE","PF00753(Lactamase_B);PF14863(Alkyl_sulf_dimr);PF14864(Alkyl_sulf_C)",5,"LEU A 124;ASP A 141;ASP A 278;VAL A 145;ILE A 138","None","1.08A","5t2zA-2yheA:undetectable","5t2zA-2yheA:10.76"],["5T2Z_B_017B201_1","2yjv","Escherichia coli","REGULATOR OF RIBONUCLEASE ACTIVITY A","PF03737(RraA-like)",5,"GLY A  67;ASP A  64;VAL A  91;GLY A 134;SER A  24","None","0.77A","5t2zA-2yjvA:undetectable","5t2zA-2yjvA:21.79"],["5T2Z_B_017B201_1","2yvq","Homo sapiens","CARBAMOYL-PHOSPHATE SYNTHASE","PF02142(MGS)",5,"ASP A1429;GLY A1361;ILE A1362;PRO A1462;ILE A1427","None","1.06A","5t2zA-2yvqA:undetectable","5t2zA-2yvqA:18.88"],["5T2Z_B_017B201_1","3b46","Saccharomyces cerevisiae","AMINOTRANSFERASE BNA3","PF00155(Aminotran_1_2)",5,"LEU A 290;GLY A 134;GLY A 127;ILE A 128;SER A 285","None","0.67A","5t2zA-3b46A:undetectable","5t2zA-3b46A:15.71"],["5T2Z_B_017B201_1","3d43","Lysinibacillus sphaericus","SPHERICASE","PF00082(Peptidase_S8)",5,"ALA A  97;ASP A  96;GLY A  92;PRO A 254;ILE A  30","None","1.03A","5t2zA-3d43A:undetectable","5t2zA-3d43A:17.11"],["5T2Z_B_017B201_1","3dbg","Streptomyces coelicolor","PUTATIVE CYTOCHROME P450","PF00067(p450)",5,"GLY A 359;ALA A 360;ASP A 361;PRO A  24;ILE A 356","None","0.84A","5t2zA-3dbgA:undetectable","5t2zA-3dbgA:11.35"],["5T2Z_B_017B201_1","3gve","Bacillus subtilis","YFKN PROTEIN","PF00149(Metallophos)",5,"GLY A 121;ALA A 122;ASP A 123;ILE A  89;ILE A 126","None","0.74A","5t2zA-3gveA:undetectable","5t2zA-3gveA:16.01"],["5T2Z_B_017B201_1","3huu","Staphylococcus haemolyticus","TRANSCRIPTION REGULATOR LIKE PROTEIN","PF13377(Peripla_BP_3)",5,"LEU A  25;GLY A 259;ALA A 262;GLY A 111;ILE A  86","None","1.06A","5t2zA-3huuA:undetectable","5t2zA-3huuA:18.01"],["5T2Z_B_017B201_1","3i4o","Mycobacterium tuberculosis","TRANSLATION INITIATION FACTOR IF-1","PF01176(eIF-1a)",5,"LEU A  27;GLY A  66;ALA A  35;VAL A  14;ILE A  25","None","1.00A","5t2zA-3i4oA:undetectable","5t2zA-3i4oA:22.33"],["5T2Z_B_017B201_1","3id3","Escherichia coli","REGULATOR OF SIGMA E PROTEASE","PF00595(PDZ)",5,"ASP A 244;GLY A 243;VAL A 247;GLY A 280;ILE A 276","None","1.04A","5t2zA-3id3A:undetectable","5t2zA-3id3A:22.77"],["5T2Z_B_017B201_1","3ifr","Rhodospirillum rubrum","CARBOHYDRATE KINASE, FGGY","PF00370(FGGY_N);PF02782(FGGY_C)",5,"ASP A 107;GLY A 108;PRO A 101;SER A 102;ILE A 103","None","1.06A","5t2zA-3ifrA:undetectable","5t2zA-3ifrA:11.92"],["5T2Z_B_017B201_1","3k4h","Bacillus cytotoxicus","PUTATIVE TRANSCRIPTIONAL REGULATOR","PF13377(Peripla_BP_3)",5,"LEU A  13;GLY A 251;ALA A 254;GLY A  99;ILE A  74","None;None;None;MAL A 501 (-3.3A);None","1.06A","5t2zA-3k4hA:undetectable","5t2zA-3k4hA:15.75"],["5T2Z_B_017B201_1","3kyh","Saccharomyces cerevisiae","MRNA-CAPPING ENZYME SUBUNIT BETA","PF02940(mRNA_triPase)",5,"ALA A 337;ASP A 336;ASP A 315;VAL A 322;ILE A 313","None","0.96A","5t2zA-3kyhA:undetectable","5t2zA-3kyhA:15.49"],["5T2Z_B_017B201_1","3lun","Methanosarcina acetivorans","ULILYSIN","PF05572(Peptidase_M43)",5,"ALA A 209;ASP A 207;VAL A 175;ILE A  93;ILE A 205","None","0.95A","5t2zA-3lunA:undetectable","5t2zA-3lunA:16.21"],["5T2Z_B_017B201_1","3mq0","Agrobacterium tumefaciens","TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON","PF01614(IclR);PF09339(HTH_IclR)",5,"LEU A 240;GLY A 254;VAL A 121;PRO A 118;ILE A 238","None","0.93A","5t2zA-3mq0A:undetectable","5t2zA-3mq0A:15.69"],["5T2Z_B_017B201_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",5,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;PRO A  81","None","1.08A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.52A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_1","3nek","Methanocaldococcus jannaschii","NITROGEN REPRESSOR-LIKE PROTEIN MJ0159","PF01995(DUF128)",5,"GLY A 457;ALA A 456;GLY A 480;ILE A 376;PRO A 511","GOL A   1 ( 4.7A);None;None;None;None","1.02A","5t2zA-3nekA:undetectable","5t2zA-3nekA:19.91"],["5T2Z_B_017B201_1","3owq","Listeria innocua","LIN1025 PROTEIN","PF03816(LytR_cpsA_psr)",5,"ALA A 169;ASP A 168;GLY A 162;ILE A 158;ILE A 244","None","1.08A","5t2zA-3owqA:undetectable","5t2zA-3owqA:15.34"],["5T2Z_B_017B201_1","3p4g","Marinomonas primoryensis","ANTIFREEZE PROTEIN","no annotation",5,"ASP A 103;GLY A  99;ALA A  98;VAL A 124;GLY A 137"," CA A 403 ( 2.4A); CA A 403 (-4.1A); CA A 404 (-4.5A);None; CA A 405 (-4.1A)","0.98A","5t2zA-3p4gA:undetectable","5t2zA-3p4gA:14.33"],["5T2Z_B_017B201_1","3qc0","Sinorhizobium meliloti","SUGAR ISOMERASE","PF01261(AP_endonuc_2)",5,"GLY A  66;VAL A 171;GLY A 123;ILE A  81;PRO A 129","None","0.92A","5t2zA-3qc0A:undetectable","5t2zA-3qc0A:16.79"],["5T2Z_B_017B201_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",5,"ASP A  32;GLY A  34;ALA A  35;VAL A  39;PRO A  89","3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-4.0A)","0.56A","5t2zA-3slzA:11.4","5t2zA-3slzA:29.82"],["5T2Z_B_017B201_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;VAL A  39;GLY A  56","None;3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-3.4A)","0.49A","5t2zA-3slzA:11.4","5t2zA-3slzA:29.82"],["5T2Z_B_017B201_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.5A);017 A 201 (-4.2A);017 A 201 (-4.0A);017 A 201 (-3.3A)","1.26A","5t2zA-3t3cA:19.1","5t2zA-3t3cA:72.73"],["5T2Z_B_017B201_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);None;017 A 201 (-4.0A);017 A 201 (-3.3A)","0.40A","5t2zA-3t3cA:19.1","5t2zA-3t3cA:72.73"],["5T2Z_B_017B201_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","SO4 A 101 (-4.2A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);None;017 A 201 (-4.0A);017 A 201 (-3.3A);None","0.54A","5t2zA-3t3cA:19.1","5t2zA-3t3cA:72.73"],["5T2Z_B_017B201_1","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-4.6A);017 A 201 (-3.0A);017 A 201 (-3.3A);017 A 201 (-4.1A);017 A 201 (-4.7A)","0.41A","5t2zA-3ttpA:20.2","5t2zA-3ttpA:77.78"],["5T2Z_B_017B201_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 (-3.4A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A)","1.29A","5t2zA-3u7sA:19.8","5t2zA-3u7sA:76.77"],["5T2Z_B_017B201_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None;017 A 202 ( 2.5A);017 A 201 ( 3.5A);017 A 201 (-3.4A);017 A 201 (-3.2A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A);017 A 202 (-4.0A)","0.36A","5t2zA-3u7sA:19.8","5t2zA-3u7sA:76.77"],["5T2Z_B_017B201_1","3uhl","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;PRO A  81","None","0.45A","5t2zA-3uhlA:16.5","5t2zA-3uhlA:77.78"],["5T2Z_B_017B201_1","3w1j","Aquifex aeolicus","L-SERYL-TRNA(SEC) SELENIUM TRANSFERASE","PF03841(SelA)",5,"LEU A 211;GLY A 202;ALA A 203;GLY A 190;ILE A 160","None","0.88A","5t2zA-3w1jA:undetectable","5t2zA-3w1jA:13.21"],["5T2Z_B_017B201_1","3wn6","Oryza sativa","ALPHA-AMYLASE","PF00128(Alpha-amylase);PF07821(Alpha-amyl_C2)",5,"GLY A  58;ASP A  52;VAL A  51;GLY A 106;ILE A  54","None","1.02A","5t2zA-3wn6A:undetectable","5t2zA-3wn6A:11.75"],["5T2Z_B_017B201_1","4a3x","[Candida] glabrata","EPA1P","PF10528(GLEYA)",5,"GLY A 172;ALA A 173;ASP A 178;PRO A  52;SER A  51","None","0.91A","5t2zA-4a3xA:undetectable","5t2zA-4a3xA:18.94"],["5T2Z_B_017B201_1","4asl","[Candida] glabrata","EPA1P","PF10528(GLEYA)",5,"GLY A 172;ALA A 173;ASP A 178;PRO A  52;SER A  51","None","0.89A","5t2zA-4aslA:undetectable","5t2zA-4aslA:20.38"],["5T2Z_B_017B201_1","4cw5","Bacillus velezensis","DFNA","PF03060(NMO)",5,"GLY A 559;GLY A 732;ILE A 731;PRO A 542;ILE A 539","FMN A1753 (-3.0A);None;None;None;None","0.99A","5t2zA-4cw5A:undetectable","5t2zA-4cw5A:13.45"],["5T2Z_B_017B201_1","4f7f","Anopheles gambiae","AGAP005208-PA","PF01395(PBP_GOBP)",5,"GLY A  80;ALA A  79;ASP A  76;SER A  66;ILE A  70","None;None;None;PG6 A 202 ( 4.4A);PG6 A 202 ( 4.9A)","1.03A","5t2zA-4f7fA:undetectable","5t2zA-4f7fA:19.17"],["5T2Z_B_017B201_1","4ida","Fragaria vesca","RIPENING-INDUCED PROTEIN","PF08240(ADH_N);PF13602(ADH_zinc_N_2)",5,"LEU A 203;GLY A 208;ALA A 209;ASP A 210;ILE A 179","None","0.88A","5t2zA-4idaA:undetectable","5t2zA-4idaA:17.34"],["5T2Z_B_017B201_1","4iqy","Homo sapiens","O-ACETYL-ADP-RIBOSE DEACETYLASE MACROD2","PF01661(Macro)",5,"GLY A 191;ALA A 149;GLY A 146;ILE A 185;ILE A 153","None","0.90A","5t2zA-4iqyA:undetectable","5t2zA-4iqyA:16.06"],["5T2Z_B_017B201_1","4kpo","Zea mays","NUCLEOSIDE N-RIBOHYDROLASE 3","PF01156(IU_nuc_hydro)",5,"GLY A  10;ASP A  12;GLY A 124;ILE A  34;ILE A  17","None; CA A 401 ( 4.8A); CA A 401 ( 4.3A);None;None","0.88A","5t2zA-4kpoA:undetectable","5t2zA-4kpoA:21.40"],["5T2Z_B_017B201_1","4mch","Aliivibrio fischeri","URIDINE PHOSPHORYLASE","PF01048(PNP_UDP_1)",5,"LEU A 176;GLY A  92;ALA A  91;GLY A 101;ILE A 104","None;DMS A 515 ( 4.1A);None;None;None","1.09A","5t2zA-4mchA:undetectable","5t2zA-4mchA:19.41"],["5T2Z_B_017B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;ILE A  84","RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-4.8A);RIT A 500 (-4.3A)","0.73A","5t2zA-4njvA:19.9","5t2zA-4njvA:85.86"],["5T2Z_B_017B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50","None;RIT A 500 (-2.4A);RIT A 500 (-3.2A);RIT A 500 (-3.4A);RIT A 500 (-4.3A)","1.03A","5t2zA-4njvA:19.9","5t2zA-4njvA:85.86"],["5T2Z_B_017B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-3.9A);RIT A 500 (-4.3A)","0.51A","5t2zA-4njvA:19.9","5t2zA-4njvA:85.86"],["5T2Z_B_017B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);None;RIT A 500 (-3.4A);RIT A 500 (-4.3A);RIT A 500 (-4.3A)","0.44A","5t2zA-4njvA:19.9","5t2zA-4njvA:85.86"],["5T2Z_B_017B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;PRO A  81;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);None;RIT A 500 (-3.4A);RIT A 500 (-3.9A);RIT A 500 (-4.3A)","0.46A","5t2zA-4njvA:19.9","5t2zA-4njvA:85.86"],["5T2Z_B_017B201_1","4pmw","Mus musculus","DIS3-LIKE EXONUCLEASE 2","PF00773(RNB);PF17216(Rrp44_CSD1)",5,"LEU A 265;ASP A 282;ILE A 303;PRO A 268;SER A 267","None;None;None;None;  U C   1 ( 3.7A)","0.84A","5t2zA-4pmwA:undetectable","5t2zA-4pmwA:7.32"],["5T2Z_B_017B201_1","4pyr","Chromobacterium violaceum","PUTATIVE BRANCHED-CHAIN AMINO ACID ABC TRANSPORTER","PF04348(LppC)",5,"ALA A 343;VAL A  88;GLY A 336;ILE A 337;ILE A  86","None","1.05A","5t2zA-4pyrA:undetectable","5t2zA-4pyrA:16.17"],["5T2Z_B_017B201_1","4tl9","Synechococcus elongatus","CIRCADIAN CLOCK PROTEIN KINASE KAIC","PF06745(ATPase)",5,"ALA A  87;GLY A 243;ILE A 239;SER A  56;ILE A  57","None;None;AGS A 303 ( 3.9A);None;None","0.85A","5t2zA-4tl9A:undetectable","5t2zA-4tl9A:19.11"],["5T2Z_B_017B201_1","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",7,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;ASP A  36;GLY A  58;ILE A 100","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);4B1 A 201 (-3.4A);4B1 A 201 (-4.8A)","0.43A","5t2zA-4ydfA:12.4","5t2zA-4ydfA:33.62"],["5T2Z_B_017B201_1","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",6,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;ASP A  36;VAL A  39","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);None","0.43A","5t2zA-4ydfA:12.4","5t2zA-4ydfA:33.62"],["5T2Z_B_017B201_1","4z38","Bacillus velezensis","MLNA","no annotation",5,"GLY A 576;GLY A 748;ILE A 747;PRO A 559;ILE A 556","FMN A 900 (-3.5A);None;None;None;None","1.01A","5t2zA-4z38A:undetectable","5t2zA-4z38A:12.36"],["5T2Z_B_017B201_1","4z38","Bacillus velezensis","MLNA","no annotation",5,"GLY A 576;GLY A 748;ILE A 747;SER A 561;ILE A 556","FMN A 900 (-3.5A);None;None;None;None","1.08A","5t2zA-4z38A:undetectable","5t2zA-4z38A:12.36"],["5T2Z_B_017B201_1","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None","0.40A","5t2zA-5b18A:17.9","5t2zA-5b18A:76.77"],["5T2Z_B_017B201_1","5ctm","Bacillus pumilus","BETA-LACTAMASE","PF00905(Transpeptidase)",5,"LEU A 262;VAL A  87;GLY A  73;ILE A 266;PRO A 197","None","1.08A","5t2zA-5ctmA:undetectable","5t2zA-5ctmA:17.17"],["5T2Z_B_017B201_1","5cwa","Mycobacterium tuberculosis","ANTHRANILATE SYNTHASE COMPONENT 1","PF00425(Chorismate_bind);PF04715(Anth_synt_I_N)",5,"LEU A 125;ASP A 447;GLY A 450;ALA A 449;ASP A 115","None","1.08A","5t2zA-5cwaA:undetectable","5t2zA-5cwaA:12.18"],["5T2Z_B_017B201_1","5erb","Bacillus amyloliquefaciens","POLYKETIDE SYNTHASE","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C);PF16197(KAsynt_C_assoc)",5,"LEU A 187;GLY A 208;ALA A 207;ILE A  14;ILE A 190","None","1.07A","5t2zA-5erbA:undetectable","5t2zA-5erbA:11.36"],["5T2Z_B_017B201_1","5g5g","Escherichia coli","PUTATIVE XANTHINE DEHYDROGENASE YAGT IRON-SULFUR-BINDING SUBUNIT","PF00111(Fer2);PF01799(Fer2_2)",5,"GLY A 211;ALA A 212;ASP A 154;GLY A 159;ILE A 216","None;None;None;FES A 230 (-4.2A);None","0.81A","5t2zA-5g5gA:undetectable","5t2zA-5g5gA:22.60"],["5T2Z_B_017B201_1","5gw4","Saccharomyces cerevisiae","T-COMPLEX PROTEIN 1 SUBUNIT GAMMA","PF00118(Cpn60_TCP1)",5,"ALA g 399;ASP g 398;GLY g 160;ILE g 165;ILE g 155","None","1.03A","5t2zA-5gw4g:undetectable","5t2zA-5gw4g:13.75"],["5T2Z_B_017B201_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",5,"GLY A 825;ALA A 824;ILE A 137;SER A 810;ILE A 814","None","1.00A","5t2zA-5lohA:undetectable","5t2zA-5lohA:14.51"],["5T2Z_B_017B201_1","5xj1","Streptococcus pneumoniae","UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029","no annotation",5,"GLY A 399;ALA A 400;ASP A 401;ILE A 373;ILE A 378","None","0.85A","5t2zA-5xj1A:undetectable","5t2zA-5xj1A:13.56"],["5T2Z_B_017B201_1","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",6,"LEU A  28;ASP A  30;GLY A  32;ALA A  33;ASP A  34;GLY A  58","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);3TL A 201 (-3.4A)","0.19A","5t2zA-6fivA:15.7","5t2zA-6fivA:30.17"],["5T2Z_B_017B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);None;None","0.64A","5t2zA-6upjA:18.4","5t2zA-6upjA:49.49"],["5T2Z_B_017B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);None","0.65A","5t2zA-6upjA:18.4","5t2zA-6upjA:49.49"],["5T2Z_B_017B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None;None","0.85A","5t2zA-6upjA:18.4","5t2zA-6upjA:49.49"],["5T2Z_B_017B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;GLY A  27;ASP A  29;ASP A  30;GLY A  49;ILE A  50;ILE A  84","None;NIU A 100 (-4.5A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.81A","5t2zA-6upjA:18.4","5t2zA-6upjA:49.49"]]